Wilmington Savings Fund Society FSB purchased a new position in Sanofi (NASDAQ:SNY – Free Report) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 3,795 shares of the company’s stock, valued at approximately $219,000.
A number of other hedge funds have also recently made changes to their positions in SNY. Lantz Financial LLC lifted its position in Sanofi by 23.2% during the second quarter. Lantz Financial LLC now owns 8,054 shares of the company’s stock valued at $391,000 after acquiring an additional 1,518 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Sanofi by 4.0% during the 2nd quarter. Fifth Third Bancorp now owns 28,701 shares of the company’s stock valued at $1,393,000 after purchasing an additional 1,096 shares during the last quarter. Atria Wealth Solutions Inc. boosted its position in shares of Sanofi by 5.3% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 20,691 shares of the company’s stock worth $1,004,000 after purchasing an additional 1,039 shares in the last quarter. &PARTNERS grew its stake in Sanofi by 153.4% during the 2nd quarter. &PARTNERS now owns 24,741 shares of the company’s stock worth $1,200,000 after buying an additional 14,979 shares during the last quarter. Finally, Planned Solutions Inc. acquired a new position in Sanofi during the 2nd quarter valued at about $246,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.
Sanofi Price Performance
NASDAQ SNY opened at $47.01 on Thursday. The stock’s fifty day moving average price is $50.56 and its 200 day moving average price is $52.05. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $119.30 billion, a price-to-earnings ratio of 23.98, a PEG ratio of 1.23 and a beta of 0.58.
Analyst Ratings Changes
SNY has been the subject of several recent analyst reports. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.50.
Check Out Our Latest Stock Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Articles
- Five stocks we like better than Sanofi
- What Are Dividend Contenders? Investing in Dividend Contenders
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What is a Stock Market Index and How Do You Use Them?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Stock Dividend Cuts Happen Are You Ready?
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.